Logo
x

Search

Subscribe Now

Neurocrine Biosciences

Neurocrine’s Crenessity (Crinecerfont) Secures the US FDA’s Approval to Treat Adults and Pediatrics with Congenital Adrenal Hyperplasia (CAH)

Neurocrine’s Crenessity (Crinecerfont) Secures the US FDA’s Approval to Treat Adults and Pediatrics with Congenital Adrenal Hyperp...

  • December 13, 2024
Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences Provides P-II (ERUDITE) Study Updates of Luvadaxistat for Cognitive Impairment Associated with Schizophreni...

  • September 13, 2024
Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD

  • April 24, 2024
Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder

  • April 4, 2024
Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenital Adrenal Hyperplasia

Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenita...

  • October 6, 2023
Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults

  • September 13, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.